Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia (NASDAQ: LQDA) announced that CEO Dr. Roger Jeffs will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at approximately 5:15 p.m. PT / 8:15 p.m. ET at the Westin St. Francis in San Francisco.
A live, audio-only webcast will be available on the company Investors page and will be archived on the website for at least 30 days.
Details
News Market Reaction – LQDA
On Jan 7, the day this news came out, LQDA closed 0.88% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference date
- January 14, 2026
- Presentation at 44th Annual J.P. Morgan Healthcare Conference
- Presentation time PT
- 5:15 p.m.
- Scheduled conference presentation start (Pacific Time)
- Presentation time ET
- 8:15 p.m.
- Scheduled conference presentation start (Eastern Time)
- Webcast archive period
- 30 days
- Minimum period webcast will remain available on company website
Historical Context
-
Announcement of November 2025 investor conference presentations and webcasts.
-
Q3 2025 results highlighting YUTREPIA launch momentum and improved profitability.
-
Scheduled Q3 2025 results release and webcast with corporate update details.
-
R&D Day announcement with updates on L606 and YUTREPIA for investors.
-
Upcoming ASCENT trial data presentations at CHEST 2025 annual meeting.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. The webcast will be archived on the company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.